A Study of ABT-888 in Patients with Solid Tumors (Phase I) and Relapsed/Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) after Prior Platinum Containing First-Line Chemotherapy

Overview

About this study

The purpose of this study is to determine the maximum tolerated dose of the combination of ABT-888 and weekly topotecan in adult patients with advanced solid tumors, and to identify any anti-tumor activity of this treatment combination, as assessed by objective response in patients with advanced solid tumors.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ³ 18 years.
  • Phase 1: Adult patients with histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative measures or other therapy definitely capable of extending life expectancy does not exist.
  • Phase 2:  All patients enrolled in the Phase 2 portion of this trial must have a history of biopsy-proven ovarian, fallopian tube or primary peritoneal cancer.
  • Patients must have received < 3 lines of prior therapy and have relapsed less than a year from their last platinum regimen.  Regimens that are used twice (for example carboplatin and paclitaxel) can be counted as one.  If a regimen is changed during the course of treatment due to side effect profile or allergy, the course of therapy is counted as one regimen. (For example, if docetaxel is substituted for paclitaxel due to a reaction during the initial course of adjuvant therapy, this is considered one regimen).
  • Patients must have measurable disease as defined in Section 11.0 with at least one lesion whose longest diameter can be accurately measured as ≥ 2.0 cm with conventional techniques or as ≥ 1.0 cm with spiral CT.  If spiral CT is used, it must be used for both pre- and post- treatment tumor assessments.
  • The following laboratory values obtained £ 7 days prior to registration:
    • Absolute neutrophil count ³ 1500/mcL;
    • Hemoglobin ≥ 9.0 g/dL;
    • Platelets ³ 100,000/mcL;
    • Total bilirubin £ 1.5 x the upper limit of normal (ULN);
    • SGPT (ALT) or SGOT (AST) £ 2.5 x ULN in the absence of hepatic metastasis.  SGPT (ALT) ≤ 3 x ULN or SGOT (AST) £ 5 x ULN in the presences of hepatic metastasis;
    • Creatinine £ 1.5 x ULN;
    • INR ≤ 1.4 unless receiving therapeutic doses of coumadin;
    • PTT ≤ 48 seconds (1.25 x ULN).
  • ECOG Performance Status (PS) 0, 1, or 2.
  • Ability to provide informed consent.
  • Willingness to return to enrolling institution for follow-up.
  • Life expectancy ³ 12 weeks.
  • Correlative Research:
    • Willingness to provide the biologic specimens is required by the protocol. This is part of the mandatory correlative research component. These specimens include:
      • Phase 1: Peripheral blood for plasma pharmacokinetic analysis and PBMC polymer assessment from 0-24 h after drug administration on days 1 and 2 of cycle 1 as well as day 2 of cycle 2; urine for assessment of ABT-888 renal clearance for 24 h after administration of drugs on days 1 and 2 of cycle 1 as well as day 2 of cycle 2; and a pretreatment peripheral blood sample for possible sequencing of the BRCA1, BRCA2 loci as well as possible pharmacogenomic analysis (see Section 14 for further information);
      • Negative urine or serum pregnancy test done ≤ 7 days prior to registration for females of child bearing potential only;
      • Able to swallow and absorb the medication.

Exclusion Criteria:

  • Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy.
  • Prior treatment with a PARP inhibitor or topotecan.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Any of the following prior therapies:
    • Chemotherapy £ 4 weeks prior to registration;
    • Mitomycin C/nitrosoureas £ 6 weeks prior to registration;
    • Immunotherapy £ 4 weeks prior to registration;
    • Biologic therapy £ 4 weeks prior to registration;
    • Radiation therapy £ 4 weeks prior to registration;
    • Radiation to > 25% of bone marrow;
    • Investigational therapy or any ancillary therapy considered investigational (utilized for a non-FDA-approved indication and in the context of a research investigation) £ 4 weeks prior to registration. Subjects with prostate cancer will be permitted to continue hormone therapy.
  • Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment.
  • New York Heart Association classification III or IV.
  • Known CNS metastases or seizure disorder. Patients with known brain metastases that have been successfully treated and stable for ≥ 6 months without requirement for corticosteroids and without seizure activity will be eligible.
  • Any of the following, because this study involves both ABT-888, an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown, and topotecan, an agent that has known genotoxic, mutagenic and teratogenic effects:
    • Pregnant women;
    • Nursing women;
    • Men or women of childbearing potential who are unwilling to employ adequate contraception.
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be HIV positive.  Note: HIV-positive patients with undetectable viral loads and CD4 counts > 300 and not on interacting retrovirals therapy are eligible after discussing with the principal investigator.
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
  • Other active malignancy, except non-melanotic skin cancer or carcinoma-in-situ of the cervix.  
    • Note: If there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer.
  • History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
  • More than 2 prior chemotherapy regimens for the current malignancy.  Full dose chemotherapy used in conjunction with concurrent radiation therapy will be included as prior therapy.
    • Note: Prior hormonal therapy (e.g. leuprolide, aromatase inhibitors, and tamoxifen) and immunotherapy will be allowed and not included as a prior chemotherapy.  If the chemotherapy regimen is altered during the course due to issues with tolerability or safety, the regimen will be counted as one. Using the same regimen at recurrence is counted as one regimen. The addition of bevacizumab to a prior regimen is considered one regimen.

 

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrea Wahner Hendrickson, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20442761

Mayo Clinic Footer